GlassScriptPhysician profile
Jonathon D Medina
NPI 1942219803
$6,297.94
in general payments reported to CMS, 2019-2025
44 companies · $962 in 2025
The $962 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $501 · 2021: $937 · 2022: $852 · 2023: $1,391 · 2024: $1,028 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $658.40 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $572.29 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $555.34 | 2019-2023 | Hetlioz, Fanapt |
| Merck Sharp & Dohme LLC | $384.31 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Lilly USA, LLC | $351.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $327.12 | 2023-2025 | Rexulti |
| Amgen INC. | $308.03 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $297.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $255.07 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $243.24 | 2019-2025 | |
| Abbvie INC. | $240.42 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $213.36 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $179.94 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $150.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.28 | 2019-2025 | Jardiance |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.